|
|
|
|
LEADER |
00000cam a2200000 a 4500 |
001 |
SCIDIR_on1141223334 |
003 |
OCoLC |
005 |
20231120010437.0 |
006 |
m o d |
007 |
cr |n||||||||| |
008 |
200223s2020 ne o 001 0 eng d |
040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d OPELS
|d UKMGB
|d UKAHL
|d OCLCF
|d EBLCP
|d OCLCQ
|d OCLCO
|d K6U
|d OCLCQ
|d OCLCO
|
015 |
|
|
|a GBC027244
|2 bnb
|
016 |
7 |
|
|a 019718644
|2 Uk
|
019 |
|
|
|a 1141511300
|
020 |
|
|
|a 9780128168769
|q (electronic bk.)
|
020 |
|
|
|a 0128168765
|q (electronic bk.)
|
020 |
|
|
|z 9780128167052
|
020 |
|
|
|z 012816705X
|
035 |
|
|
|a (OCoLC)1141223334
|z (OCoLC)1141511300
|
050 |
|
4 |
|a RS201.N35
|
082 |
0 |
4 |
|a 620/.5
|2 23
|
245 |
0 |
0 |
|a Nanomaterials for clinical applications :
|b case studies in nanomedicines /
|c edited by Natassa Pippa and Costas Demetzos.
|
260 |
|
|
|a Amsterdam :
|b Elsevier,
|c 2020.
|
300 |
|
|
|a 1 online resource
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Micro and nano technologies
|
500 |
|
|
|a Includes index.
|
505 |
0 |
|
|a Front Cover -- Nanomaterials for Clinical Applications -- Copyright Page -- Contents -- List of contributors -- 1. Solid lipid nanoparticles in dermaceuticals -- 1.1 General introduction -- 1.2 Why solid lipid nanoparticles? -- 1.2.1 Formulation aspects -- 1.2.2 Physiological aspects -- 1.3 Evolution of lipidic nanoparticles from solid lipid nanoparticles to nanostructured lipid carriers -- 1.4 Cosmetic and topical applications of solid lipid nanoparticles -- 1.5 Skin penetration with solid lipid nanoparticles -- 1.6 Mechanism of drug penetration with solid lipid nanoparticles
|
505 |
8 |
|
|a 1.7 Incorporation into semisolid vehicle -- 1.8 Case studies of successful topical delivery with lipidic nanoparticles -- 1.8.1 Delivery of antimicrobials -- 1.9 Delivery of agents for other skin diseases -- 1.9.1 Solid lipid nanoparticles for cosmetic applications -- 1.10 Conclusions -- References -- 2. Cyclodextrin-based drug delivery systems -- 2.1 Cyclodextrins-structure, physiochemical properties, and toxicological profile -- 2.2 Cyclodextrin inclusion complexes-formation, stability, and application in drug delivery -- 2.3 Cyclodextrin-based products in clinical practice
|
505 |
8 |
|
|a 2.3.3.1 Cyclodextrins in control of obesity and hyperlipidemia -- References -- 3. Lipid vesicles for (trans)dermal administration -- 3.1 (Trans)dermal drug-delivery systems -- 3.1.1 Human skin barrier to xenobiotics -- 3.2 Lipid vesicles for breaching the skin barrier -- 3.2.1 Conventional liposomes -- 3.2.2 Transfersomes -- 3.2.3 Ethanol-based lipid vesicles -- 3.2.3.1 Ethosomes -- 3.2.3.2 Transethosomes -- 3.2.3.3 Other lipid vesicles -- 3.3 Liposomal formulation in clinics -- 3.3.1 Conventional liposomes -- 3.3.2 Transfersomes -- 3.3.3 Ethosomes -- 3.4 Final remarks -- References
|
505 |
8 |
|
|a 4. Stimuli-responsive nanocarriers for drug delivery -- 4.1 Introduction -- 4.2 Types of stimuli -- 4.2.1 pH-responsive nanosystems -- 4.2.2 Thermoresponsive nanosystems -- 4.3 Development of chimeric stimuli-responsive liposomes with incorporated stimuli-responsive polymers -- 4.3.1 pH-responsive liposomes -- 4.3.2 Thermoresponsive liposomes -- 4.4 Thermotropic behavior of stimuli-responsive liposomes -- 4.4.1 Thermal analysis on pH-responsive liposomes -- 4.4.2 Thermal analysis of thermoresponsive liposomes -- 4.5 Physicochemical properties of stimuli-responsive liposomes
|
650 |
|
0 |
|a Nanoparticles.
|
650 |
|
2 |
|a Nanoparticles
|0 (DNLM)D053758
|
650 |
|
6 |
|a Nanoparticules.
|0 (CaQQLa)201-0262530
|
650 |
|
7 |
|a Nanoparticles
|2 fast
|0 (OCoLC)fst01032624
|
700 |
1 |
|
|a Pippa, Natassa.
|
700 |
1 |
|
|a Demetzos, Costas.
|
776 |
0 |
8 |
|i Print version:
|t Nanomaterials for clinical applications.
|d Amsterdam : Elsevier, 2020
|z 012816705X
|z 9780128167052
|w (OCoLC)1109769616
|
830 |
|
0 |
|a Micro & nano technologies.
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128167052
|z Texto completo
|